Antitrypanosomal therapy for chronic Chagas' disease [1]

New England Journal of Medicine

Volumn 365, Issue 13, 2011, Pages 1258-1259

  Garcia Bournissen, Facundo ^a   Altcheh, Jaime ^a  

^a HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

BENZNIDAZOLE; ANTITRYPANOSOMAL AGENT; NITROIMIDAZOLE DERIVATIVE;

CHAGAS DISEASE; CHILD; CHILD HEALTH; CHRONIC DISEASE; DISEASE TRANSMISSION; DRUG BLOOD LEVEL; DRUG CLEARANCE; HEART DISEASE; HUMAN; LETTER; PREVALENCE; PRIORITY JOURNAL; ANIMAL; FEMALE; NOTE; TRYPANOSOMA CRUZI;

ANIMALS; CHAGAS DISEASE; FEMALE; HUMANS; NITROIMIDAZOLES; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 80053367214     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1108653     Document Type: Letter

References (5)

1. Bern C. Antitrypanosomal therapy for chronic Chagas' disease. N Engl J Med 2011;364:2527-34.
2. Altcheh J, Moscatelli G, Moroni S, Garcia-Bournissen F, Freilij H. Adverse events after the use of benznidazole in infants and children with Chagas disease. Pediatrics 2011;127(1):e212-e218.
3. Altcheh J, Moscatelli G, Mastrantonio G, et al. Population pharmacokinetics study of benznidazole in children with Chagas disease. Basic Clin Pharmacol Toxicol 2010;107:Suppl 1:173. abstract.
4. Schmunis GA, Yadon ZE. Chagas disease: a Latin American health problem becoming a world health problem. Acta Trop 2010;115:14-21.
5. Yadon ZE, Schmunis GA. Congenital Chagas disease: estimating the potential risk in the United States. Am J Trop Med Hyg 2009;81:927-33. [Erratum, Am J Trop Med Hyg 2010;82:518.]